Reducing the activity of a specific protein could provide significant relief for many heart failure patients.

Advanced imaging may be able to help certain heart patients avoid the risks and discomfort associated with right heart catheterizations.

There is a risk of users making adjustments during treatment that are unnecessary. The FDA is still evaluating the issue at this time.

The company's implantable Barostim device continues to make an impact on patient care. CVRx also shared excitement about the year ahead, pointing to an important new clinical trial.

Most patients hospitalized for HFrEF are still not being prescribed quadruple medical therapy at discharge. Even those who are, researchers noted, still face a high risk of dying or returning to the hospital for heart failure-related symptoms. 

The BioCardia delivery catheter was designed to be used by interventional cardiologists, electrophysiologists or cardiac surgeons. It includes a tiny needle that directly engages with the patient’s cardiac tissue. 

All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell.

Abdominal obesity, the phenomenon commonly known as “beer belly," may be associated with significant risks, including heart failure. Researchers urged cardiologists and radiologists alike to keep these findings in mind going forward.